Intrathecal Injection of Mesenchymal Stem Cells in Central Nervous System injury2017
| Registry | NCT03291366 |
|---|---|
| Status | Unknown |
| Phase | Phase 1 / Phase 2 |
| Study type | Interventional; randomized, parallel, masking: none, treatment |
| Enrollment | 30 (Estimated) |
| Sponsor | Fuzhou General Hospital (Other) |
| Conditions | Central Nervous System Injury |
| Interventions | UCMSCC, conventional treatment (Drug) |
| Dates | start 2017-01-01, primary completion 2020-01-01 (estimated), completion 2022-01-01 (estimated), first posted 2017-09-25, last updated 2017-09-25 |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Central Nervous System Injury All trials of UCMSCC All trials of conventional treatment
Central nervous system (CNS) injury leads to morbidity in patients, which has few good rehabilitation measures. Mesenchymal stem cells seem to have regenerative and tissue-repairing capabilities. The investigators design this study to infuse mesenchymal stem cells (MSCs) intrathecally to CNS injury patients, and observe the safety and efficacy by recording the change of nervous system scores, trying to prove the effect of MSC in rehabilitate CNS injury.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| MSC | Experimental | Drug: UCMSCC; Drug: conventional treatment | infusion of aUCMSC and conventional therapy |
| conventional | Active comparator | Drug: conventional treatment | conventional therapy |
Sex: All, ages: 18 Years to 65 Years
Inclusion Criteria: * CNS injury > 3 months * age > 18 years * willing to give consent * stable vital signs * absence of active infectcion Exclusion Criteria: * any contradiction to intrathecal infusion * age < 18 years * CNS injury < 3 months * CNS injury > 3 years